Stryker delivered a rare double miss in the third quarter and paired it with its first guidance cut of the year. Adjusted EPS of $3.52 fell 2.5% short of the $3.56 consensus and below the $3.61 Earnings Whisper number. Revenue of $6.52 billion missed the $6.58 billion consensus by 0.9%. On paper, earnings growth of 10.3% and revenue growth of 7.6% look healthy for a large-cap medtech. But the slowdown is the story. Organic growth decelerated to 7.7% from 9% in the second quarter and 11% in the fourth quarter of 2025. CEO Kevin Lobo conceded the quarter "did fall short of our expectations." The central tension is that Stryker's margin and cash machine is working while its top-line engine, particularly in orthopaedic reconstruction, is losing speed.

The quality of the earnings line is better than the headline miss implies. Adjusted gross margin rose 40 basis points to 65.4%, and adjusted operating margin expanded 60 basis points to 26.2%. Adjusted EPS grew double digits even though the adjusted tax rate climbed to 16.0% from 14.0%. GAAP results are a different picture. Reported EPS fell 11.7% to $1.96 and reported operating margin dropped to 15.9% from 18.7%, weighed down by:

• a $293 million goodwill impairment;
• $77 million of charges tied to the Spinal Implants sale;
• elevated structural optimization costs, including the termination of sales relationships in certain countries.

Year-to-date operating cash flow of $3.3 billion, up 14%, supported $1.0 billion in third-quarter buybacks and a new $3.0 billion repurchase authorization.

The call explained where growth went. MedSurg and Neurotechnology held up well, with 9.1% organic growth. U.S. Endoscopy rose 13% and Medical 10%, and the capital order book remained elevated with no cancellations. Orthopaedics told a different story:

• U.S. knees grew just 1.3%, versus 6.2% in the second quarter and 7.6% in the fourth quarter of 2025.
• U.S. hips declined 0.6%, versus 4.9% growth in the second quarter.

Management cited a hip and knee market growing only about 2.5% year to date and slowing further in the third quarter. It blamed higher deductibles, rising pre-authorization denials, and soft demand in Europe and the Middle East. More troubling for the long-term thesis, Stryker is now only matching market growth after years of claimed 200-300 basis point outperformance. Mako RPS and Triathlon Gold adoption are behind plan. A July SAP rollout in orthopaedics disrupted order entry and commercial focus, hitting core trauma as well, where U.S. Trauma and Extremities growth slowed to 4.5% from 12.5% in the second quarter. U.S. Vascular rebounded to 13% from -6.7%, but that bounce was aided by one-time China joint-venture milestone revenue, and peripheral vascular supply constraints persist.

Guidance is where the damage concentrates. Full-year organic growth guidance fell to 6.5%-7% from 8.3%-9.3%, and adjusted EPS guidance dropped to $14.80-$14.90 from $14.95-$15.10. Management also lifted the low end of its tax-rate range. Its weighted-average market growth assumption now sits below the roughly 6% framework from the 2025 investor day, and 2027 was framed only as growth at the high end of markets. The tone shift is stark. Last quarter's talk of regained momentum and a strong second half gave way to Lobo saying he "would have preferred to deliver better news."

There are offsetting catalysts:

• a strategic investment in CMR Surgical, with exclusive U.S. sales agency for the Versius Plus soft-tissue robot and a stated intent to eventually acquire;
• the ZuriMed acquisition in sports medicine;
• a powered hip impactor planned for 2027;
• Sonopet 3 clearance;
• expected AVS IVL approval around year-end.

The announced CEO transition to Spencer Stiles adds another variable. On the risk side, a new competitive orthopaedic robot from Monogram is expected in 2027, and orthopaedic pricing is slightly negative.

Investors were already leaning cautious. Earnings Whispers sentiment slipped from modestly positive (0.088) to modestly negative (-0.093), a meaningful but not dramatic deterioration. Shares closed at $304 ahead of the report, 7.9% below the open following the July report and 6.3% beneath the 200-day moving average. The stock set a 52-week low of $267 in mid-September and had recovered nearly 14% off that level. It still sat about 13% below the August high of $349.77. That rebound left little cushion for a guidance cut of this size.

The bottom line is that Stryker's profitability and capital-return story remains intact, but the growth premium is under pressure. Bulls can point to margin expansion, strong MedSurg demand, and new robotic and pipeline catalysts. Bears have legitimate ammunition in decelerating recon growth, lost share momentum, self-inflicted SAP disruption, and a reset market-growth framework. Until hip and knee trends stabilize and execution issues clear, the burden of proof has shifted to management.